[
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 588
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 350
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 252
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 210
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 154
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 154
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 56
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 42
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 5180
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 770
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 2212
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 98
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 70
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 2128
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 490
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 70
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 252
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 56
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 294
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 126
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 602
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 112
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 210
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 280
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 420
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 98
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 56
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 182
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 0,
    "day_time_point": 0,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 280
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 120960,
    "day_time_point": 120960,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 84
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 112
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 126
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 266
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 241920,
    "day_time_point": 241920,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 362880,
    "day_time_point": 362880,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 448
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 1554
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 378
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 28
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 196
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  },
  {
    "study_id": "GS-US-454-4378",
    "therapeutic_area": "Inflammation",
    "name": "ATLAS NASH Combo Trial (Ph. 2)",
    "time_point": 483840,
    "day_time_point": 483840,
    "subjects": 14
  }
]